Compare Entergy Corporation (ETR) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Entergy Corporation vs Organon & Co. Common Stock — how do they compare? Entergy Corporation trades at $103.92 (market cap $50.16B), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: Entergy Corporation is far larger — about 13.9× Organon & Co. Common Stock's market cap, and Entergy Corporation pays the higher dividend (2.44%). Which is the better fit depends on your goals — on Pluang, investors hold Entergy Corporation for 13 Days and Organon & Co. Common Stock for 0 Days on average.
| ETR | OGN | |
|---|---|---|
Market Cap | $50.16B | $3.62B |
Volume | 2,603,991 | 2,892,999 |
Sector | Utilities | Health |
52-Week High | $117.91 | $13.81 |
52-Week Low | $91.19 | $5.70 |
Typical Hold Time | 13 Days | 0 Days |
Enterprise Value | $80.94B | $11.04B |
Dividend Yield | 2.44% | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Entergy Corporation (ETR) trades at $104.99, up 0.96% with a bullish technical signal despite overbought RSI readings. The stock shows strong fundamentals with 13.48% net margins and consistent earnings beats in recent quarters. Recent developments include $13.7M in federal grid funding and new data center agreements benefiting customers. Analyst consensus remains strongly positive with 59% buy ratings and a $123.17 price target representing 17% upside potential.
ETR presents a compelling investment case with stable utility operations, improving cash flows, and strategic grid investments. However, elevated valuation multiples and institutional selling activity warrant caution. The stock's proximity to resistance at $105 suggests near-term consolidation may precede further gains if earnings momentum continues through Q3 results.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Entergy Corporation
Entergy is an energy company that operates regulated electric utilities and power generation businesses in the United States. Its generation portfolio includes nuclear, natural gas, and renewable resources.
Read more on ETR →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
